Literature DB >> 2671144

Vancomycin. A new old agent.

M J Ingerman1, J Santoro.   

Abstract

Interest in vancomycin has been rekindled by the emergence of resistant gram-positive pathogens and the improvement in drug purity. The antimicrobial activity, pharmacokinetics, clinical indications, dosing schedules, and adverse reactions of vancomycin are summarized.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2671144

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  5 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Pengxin Lin; Karim Calis; Amy M Kelaher; Heidi A Muray; Christine Mya-San; Diana Mickiene; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 3.  An updated comparison of drug dosing methods. Part IV: Vancomycin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

4.  Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach.

Authors:  Qingxia Liu; Huiping Huang; Baohua Xu; Dandan Li; Maobai Liu; Imam H Shaik; Xuemei Wu
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

5.  Iterative Chemical Engineering of Vancomycin Leads to Novel Vancomycin Analogs With a High in Vitro Therapeutic Index.

Authors:  Nigam M Mishra; Izabela Stolarzewicz; David Cannaerts; Joris Schuermans; Rob Lavigne; Yannick Looz; Bart Landuyt; Liliane Schoofs; Dominique Schols; Jan Paeshuyse; Peter Hickenbotham; Martha Clokie; Walter Luyten; Erik V Van der Eycken; Yves Briers
Journal:  Front Microbiol       Date:  2018-06-07       Impact factor: 5.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.